Patentability of Chemical Selection Inventions: The Olanzapine and Escitalopram Decisions

Hyewon Ahn

doi:10.5771/9783845232188

Summary

Das Werk befasst sich mit Auswahlerfindungen im Hinblick auf die jüngsten Entscheidungen des BGH zur Patentierbarkeit chemischer Verbindungen. Rechtsvergleichend stellt die Autorin die Auswirkungen dieser Rechtsprechung auf die Entwicklung der Patentgesetze und ähnlicher Gerichtsentscheidungen in den wichtigsten Rechtsordnungen dar. Die Darstellung ist darüber hinaus für Auswahlerfindungen im Bereich der Pharmaindustrie besonders hilfreich.

Search publication

Bibliographic data

Copyright year: 2011
ISBN-Print: 978-3-8329-6524-2
ISBN-Online: 978-3-8452-3218-8
Publisher: Nomos, Baden-Baden
Series: Munich Intellectual Property Law Center - MIPLC Studies
Volume: 12
Language: English
Pages: 76
Product type: Book Titles

Titelei/InhaltsverzeichnisPages 2 - 10 Download chapter (PDF)
IntroductionPages 11 - 16 Download chapter (PDF)
1. Markush type claimPages 17 - 17 Download chapter (PDF)
2. Enantiomers and Related Patents Download chapter (PDF)
1. 1. Facts in OlanzapinePages 21 - 21 Download chapter (PDF)
  2. Facts in Escitalopram Download chapter (PDF)
2. 1. Download chapter (PDF)
    1. 1. Federal Patent Court Decision
      2. Federal Court of Justice Decision
    2. 1. Federal Patent Court Decision
      2. Federal Court of Justice Decision
  2. Download chapter (PDF)
    1. Markush Claim – Olanzapine Decision
    2. Enantiomer Invention – Escitalopram Decision
  3. Download chapter (PDF)
    1. 1. Patent Court Decision
      2. Court of Appeal Decision
    2. Enantiomer Invention – Escitalopram Decision
  4. SummaryPages 31 - 31 Download chapter (PDF)
3. 1. Download chapter (PDF)
    1. Markush Claim – Olanzapine Decision
    2. Enantiomer Invention – Escitalopram Decision
  2. Download chapter (PDF)
    1. Markush Claim – Olanzapine Decision
    2. Enantiomer Invention – Escitalopram Decision
  3. Download chapter (PDF)
    1. 1. Patent Court Decision
      2. Court of Appeal Decision
    2. 1. Court of Appeal Decision
      2. The House of Lords Decision
  4. SummaryPages 37 - 38 Download chapter (PDF)
4. Summary and ConclusionPages 38 - 38 Download chapter (PDF)
1. 1. Relativity of NoveltyPages 39 - 42 Download chapter (PDF)
  2. Enablement as a Requirement for AnticipationPages 42 - 44 Download chapter (PDF)
  3. Download chapter (PDF)
    1. The Test of Anticipation: Precedent Test of Obviousness?
    2. A Possible Ground for Challenging the Basic Patent
    3. Other Implications of the Rules for Disclosure in the Olanzapine Case
  4. ConclusionPages 47 - 48 Download chapter (PDF)
2. 1. Download chapter (PDF)
    1. Size of the Genus
    2. Structural Similarity
    3. Reasonable Expectation of Success
  2. Download chapter (PDF)
    1. Teach away
    2. Unexpected Results
    3. Other Secondary Considerations
  3. Download chapter (PDF)
    1. Person Skilled in the Art in the Olanzapine Decision
    2. Reasonable Expectation of Success: Escitalopram Decision
  4. ConclusionPages 54 - 54 Download chapter (PDF)
3. 1. Easier Extension of Exclusive Right: “Evergreening” or “Life-Cycle Management”Pages 54 - 55 Download chapter (PDF)
  2. Download chapter (PDF)
    1. Scope of a Selection Invention over a Basic Patent
    2. 1. Reverse Doctrine of Equivalence
      2. Patent Act Consideration – Compulsory License
      3. Competition Law Consideration – the Orange Book Standard Decision
    3. Conclusion
4. 1. Download chapter (PDF)
    1. Clopidogrel Decision
    2. Atorvastatin Decision
  2. Selection Inventions in JapanPages 63 - 64 Download chapter (PDF)
  3. Summary and ConclusionPages 64 - 64 Download chapter (PDF)
ConclusionPages 65 - 66 Download chapter (PDF)
AbstractPages 67 - 68 Download chapter (PDF)
List of Works CitedPages 69 - 76 Download chapter (PDF)